Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 1:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Levetiracetam Clear all
Not listed Phase 4 Interventional

Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?

NCT03054285
View directory record Official record
Conditions
Seizures, Traumatic Brain Injury
Interventions
Levetiracetam
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
2,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 3 Interventional

Levetiracetam Treatment of Tardive Dyskinesia

NCT00291213
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
levetiracetam, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 5, 2014 · Synced Sep 29, 2026, 1:28 AM EDT
Withdrawn Phase 3 Interventional

Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus

NCT02726867
View directory record Official record
Conditions
Epilepsy, Status Epilepticus
Interventions
levetiracetam, lacosamide, Ketamine, Phenobarbital
Drug
Lead sponsor
Mid-Atlantic Epilepsy and Sleep Center, LLC
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2017 · Synced Sep 29, 2026, 1:28 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease

NCT04833907
View directory record Official record
Conditions
Canavan Disease
Interventions
rAAV-Olig001-ASPA, Levetiracetam, Prednisone
Drug
Lead sponsor
Myrtelle Inc.
Industry
Eligibility
3 Months to 60 Months
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)

NCT01044758
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI)
Interventions
Levetiracetam 62.5mg, Levetiracetam 125mg, Levetiracetam 250mg, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 85 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia

NCT02199509
View directory record Official record
Conditions
Oromandibular Dystonia, Cranial Dystonia
Interventions
Levetiracetam
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 4 Interventional Results available

1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients

NCT02334722
View directory record Official record
Conditions
Brain Neoplasms, Brain Cancer, Brain Tumors, Cancer of the Brain, Cancer of Brain, Seizure
Interventions
Levetiracetam
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Levetiracetam in Cocaine-Abusing Methadone Maintained Patients

NCT00577005
View directory record Official record
Conditions
Cocaine Dependence, Opioid Dependency
Interventions
levetiracetam, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Results available

Levetiracetam for the Treatment of Alcohol Dependence and Anxiety

NCT00141115
View directory record Official record
Conditions
Alcoholism, Generalized Anxiety Disorder, Panic Disorder, Social Phobia, Anxiety Disorders
Interventions
levetiracetam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Balance and Anti-Epileptic Drugs

NCT03338478
View directory record Official record
Conditions
Epilepsy
Interventions
Wii Balance Board
Diagnostic Test
Lead sponsor
Erik J. Kobylarz
Other
Eligibility
16 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 29, 2026, 1:28 AM EDT
Recruiting Phase 2 Interventional

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717
View directory record Official record
Conditions
Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
Interventions
Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 29, 2026, 1:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Premenstrual Dysphoric Disorder and Antiepileptic Drugs

NCT00612235
View directory record Official record
Conditions
Epilepsy
Interventions
Lamotrigine, Levetiracetam, Carbamazepine, No Intervention
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Treating Hyperexcitability in AD With Levetiracetam

NCT03875638
View directory record Official record
Conditions
Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
Interventions
Levetiracetam, Placebo oral capsule
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Levetiracetam 1g Under Fasted Conditions

NCT00826722
View directory record Official record
Conditions
Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 29, 2026, 1:28 AM EDT
Completed No phase listed Observational

UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)

NCT00345475
View directory record Official record
Conditions
Birth Defects, Pregnancy Complications, Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
UCB Pharma
Industry
Eligibility
Female only
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Sep 29, 2026, 1:28 AM EDT
Terminated Phase 2Phase 3 Interventional

Augmentation Study of Levetiracetam in Obsessive Compulsive Disorder

NCT00299611
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Sertraline, Levetiracetam, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fed Conditions

NCT00826787
View directory record Official record
Conditions
Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Levetiracetam 1g Tablets Under Fed Conditions

NCT00827320
View directory record Official record
Conditions
Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 29, 2026, 1:28 AM EDT
Recruiting Phase 3 Interventional

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

NCT06907173
View directory record Official record
Conditions
Status Epilepticus
Interventions
Levetiracetam (LEV) (60 mg/Kg) + 1 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg) + 3 mg/kg Ketamine (KET), Levetiracetam (LEV) (60 mg/Kg)
Drug
Lead sponsor
University of Virginia
Other
Eligibility
1 Year and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
63
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacological Modulation of Hippocampal Activity in Psychosis 2

NCT04559529
View directory record Official record
Conditions
Schizophrenia; Psychosis
Interventions
Levetiracetam (LEV) 500 mg, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2024 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy

NCT02201251
View directory record Official record
Conditions
Epilepsy
Interventions
Topiramate, Levetiracetam
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years to 15 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Gulf Breeze, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 3 Interventional Results available

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

NCT01484977
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
30
States / cities
Huntsville, Alabama • Phoenix, Arizona • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma

NCT00404248
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
terameprocol, pharmacological study
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 29, 2026, 1:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures

NCT00884052
View directory record Official record
Conditions
Seizures, Disorder of Fetus or Newborn
Interventions
Low dose levetiracetam, High dose levetiracetam
Drug
Lead sponsor
Richard H. Haas
Other
Eligibility
1 Minute to 14 Days
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 29, 2026, 1:28 AM EDT